Medical Science Monitor : International Medical Journal of Experimental and Clinical Research>Med Sci Monit. 25, 2019>5776–5784
Background: The purpose of this study was to investigate the role and mechanism of steroid receptor coactivator-interacting protein (SIP) in an astrocyte model of 1-methyl-4-phenylpyridinium (MPP+)-induced Parkinson’s disease. Material/Methods: To perform our study, a Parkinson’s disease cell model was established by treating the rat glioblastoma cell line C6 with MPP+. SIP was overexpressed in C6 cells using SIP-plasmid. Cell viability and apoptosis were analyzed using MTT assay and flow cytometer respectively. Tumor necrosis factor (TNF)-α and interleukin (IL)-1β levels were detected using enzyme linked immunosorbent assay and quantitative reverse transcription PCR. Besides, lactate dehydrogenase (LDH) release, reactive oxygen species (ROS) production, and superoxide dismutase (SOD) enzyme activity were determined in the present study. For protein and mRNA detection, western blot assay, and qRT-PCR were performed respectively. Results: SIP was decreased in MPP+-induced C6 cells. SIP overexpression relieved MPP+-induced cytotoxicity of C6 cells, displayed as increased cell viability and reduced cell apoptosis and reduced LDH release. Besides, SIP inhibited MPP+-induced inflammatory response and oxidative stress, evidenced by decreased levels of inflammatory factors (TNF-α and IL-1β), reduced ROS generation and enhanced SOD activity. Moreover, MPP+-induced nuclear factor-κB activation was inhibited by SIP overexpression. Conclusions: SIP was downregulated in Parkinson’s disease and it played a protective role in the development Parkinson’s disease, thus may be a promising target for Parkinson’s disease treatment.
Department of Neurology, Cangzhou Central Hospital, Cangzhou, Hebei, P.R. China
Katunina EA, Titova NV, Malykhina EA, et al. [Oxidative stress and Parkinson’s disease: Mechanisms and perspectives of treatment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115:141–45. [in Russian]
Erekat NS, Al-Jarrah MD. Interleukin-1 beta and tumor necrosis factor alpha upregulation and nuclear factor kappa B activation in skeletal muscle from a mouse model of chronic/progressive Parkinson disease. Medical science monitor: international medical journal of experimental and clinical research. 2018;24:7524.
Sybertz E, Krainc D. Development of targeted therapies for Parkinson’s disease and related synucleinopathies. J Lipid Res. 2014;55:1996–2003.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.